PCOM Study Improves Motor Function of SBMA MiceAugust 17, 2023
A combination approach of increasing the SIRT3 protein and inhibiting PARPs (poly-ADP
ribose polymerase) helps rescue motor endurance of mice modeling the neuromuscular
disease spinal bulbar and muscular atrophy (SBMA), also known as Kennedy's disease,
according to a new study by Philadelphia College of Osteopathic Medicine (PCOM) researchers.
SBMA is an adult-onset genetic disorder that affects men due to a mutation in the
androgen receptor gene, making the protein form a long glutamine expansion (polyglutamine)
that is toxic to motor neurons and skeletal muscle. Men suffer with progressive difficulty
walking, speaking and swallowing, usually resulting in the need for mobility aides,
and potentially feeding and respiratory support as they age. There is no cure or disease-modifying
therapy available at this time, so SBMA research seeks to identify ways to improve
muscle function for these patients.
The study, published in iScience, was led by Heather L. Montie, PhD, an associate professor of Neuroscience, Physiology and Pharmacology at PCOM, and
the primary author is David Garcia Castro, DO, PhD '23, now an anesthesiology resident at Yale. The study first examined how activating
or increasing SIRT3—a protein in the sirtuin family that regulates mitochondrial and
metabolic function—could reduce oxidative stress and death of cells modeling SBMA.
This approach looked promising in cell models, but it wasn’t nearly as effective in
mice, though overexpressing the SIRT3 protein resulted in a trend in motor recovery,
as well as a correction of a metabolic pathway involved in energy production known
as the TCA cycle.
From there, the research team sought to boost blunted SIRT3 activity by giving it
more of its diminished molecular fuel, NAD+ (an acronym to describe a molecule that's
critical to proper cell function). The team found that mice modeling SBMA have very
low levels of SIRT3 protein, and its molecular fuel, NAD+, is also severely diminished.
That means that, even in cells that were given more SIRT3, “it was not able to work
as well as it should,” Montie said, due to the low fuel source.
Since NAD+ is diminished in SBMA but critical to SIRT3 activity and overall metabolism,
the team focused on restoring NAD+ in mice modeling SBMA. That's where PARPs, proteins
that aid in repairing damaged DNA, came into the study. When PARPs are active they
use up a lot of NAD+, and they could have potentially contributed to the low NAD+
in the SBMA mice.
Although the researchers found that inhibition of PARPs did not rescue reduced NAD+
in the skeletal muscle of mice modeling SBMA, increasing SIRT3 and inhibiting PARPs
fully restored hexokinase, the initial enzyme of glycolysis, which is a cellular pathway
critical for energy production. This combination treatment rescued exercise endurance
of the mice modeling SBMA.
This combination approach that targets the metabolic anomalies in SBMA restored motor
function “downstream” of the disease-causing protein, polyglutamine-expanded (mutant)
androgen receptor. That means the toxic, disease-initiating proteins still exist,
but the mess they make—disruption of “multiple cellular processes, including mitochondrial
function, metabolism, and energy production,” according to the authors—could be fixed
up enough to reduce the burden of disease.
“As researchers develop strategies to reduce the toxic protein, perhaps we could layer
on treatments like this to further boost the restoration of muscle function,” Montie
said. “It's exciting that we can make an effective change without targeting that toxic
In the study, the mice treated with increased SIRT3 and PARP inhibition doubled the
time they spent running on a treadmill, illustrating that muscle endurance—more than
other measures, such as grip strength—significantly improved. That effect points back
to the importance of metabolism, which is severely disrupted in SBMA, and its critical
role in maintenance of muscle function.
The work was supported by PCOM's Division of Research and Center for Chronic Disorders of Aging, the Guinta Family Research Scholarship, and the United States Department of Agriculture.
“I’ll Be the Doctor They Said I’d Never Become”LeeAnn Tanaka, DO '14 - Women in Medicine MonthIf He Won the Lottery, He'd Still Come To Work Every Day
About Philadelphia College of Osteopathic Medicine
Founded in 1899, Philadelphia College of Osteopathic Medicine (PCOM) has trained thousands
of highly competent, caring physicians, health practitioners and behavioral scientists
who practice a “whole person” approach to care—treating people, not just symptoms.
PCOM operates three campuses (PCOM, PCOM Georgia and PCOM South Georgia) and offers doctoral degrees in clinical psychology, educational psychology, osteopathic
medicine, pharmacy, physical therapy and school psychology, and graduate degrees in
applied behavior analysis, applied positive psychology, biomedical sciences, forensic
medicine, medical laboratory science, mental health counseling, non profit leadership
and population health management, organizational development and leadership, physician
assistant studies, school psychology, and public health management and administration.
PCOM students learn the importance of health promotion, research, education and service
to the community. Through its community-based Healthcare Centers, PCOM provides care
to medically underserved populations. For more information, visit pcom.edu or call 215-871-6100.
For more information, contact:
Executive Director, Strategic Communications
Office: 215-871-6312 | Cell: